Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17714540 | 0.98 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2OPRD1 | |
| SCHEMBL22319499 | 0.94 | HPGD (0.44) | USP2SMN1; SMN2HPGDEPHX2OPRD1 | |
| SCHEMBL9773945 | 0.90 | USP2 (0.42) | USP2SMN1; SMN2HPGDEPHX2OPRD1 | |
| SCHEMBL2140971 | 0.87 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2OPRD1 | |
| SCHEMBL25845775 | 0.85 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2OPRD1 | |
| SCHEMBL18418212 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2OPRD1 | |
| SCHEMBL2349423 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL2945193 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL18669304 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2HPGDEPHX2OPRD1 | |
| SCHEMBL12691337 | 0.84 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070930-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-03-12 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388608-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4608839-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | Protego Biopharma, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250197423-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-19 | — | — | US | disclosed |
| EP-3321268-B1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-20250145643-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-05-08 | — | — | US | disclosed |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1349847-B1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| WO-2005016346-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050043334-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. | 2005-02-24 | — | — | US | disclosed |
| CN-1481376-A | HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS | ���ĵ�˹ҩ��¹�����˾ | 2004-03-10 | — | — | CN | disclosed |
| EP-1349847-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070930-A1 | RAS INHIBITORS | KRAS, NRAS, RIN1 | USP2 2484/4885SMN1; SMN2 4241/4885HPGD 1566/4885 |
| US-20250145643-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | USP2 1149/4885SMN1; SMN2 3728/4885HPGD 3002/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | USP2 2102/4885SMN1; SMN2 4495/4885HPGD 1695/4885 |
| US-20250197423-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | USP2 1149/4885SMN1; SMN2 3728/4885HPGD 3002/4885 |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | F12, F11, F5 | USP2 1131/4885SMN1; SMN2 2054/4885HPGD 1042/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | USP2 2509/4885SMN1; SMN2 3360/4885HPGD 427/4885 |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | USP2 3336/4885SMN1; SMN2 3830/4885HPGD 2397/4885 |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | MEN1, MLLT1, MSI2 | USP2 3835/4885SMN1; SMN2 2354/4885HPGD 2181/4885 |
| US-20250388608-A1 | RAS INHIBITORS | KRAS, NRAS, HMGCR | USP2 2102/4885SMN1; SMN2 4495/4885HPGD 1695/4885 |
| US-20050043334-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | USP2 3543/4885SMN1; SMN2 4722/4885HPGD 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.